Latest From Genfit SA
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.
2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.
Privately held biotech plans to move insulin sensitizer into Phase III with ambitious goals of obtaining accelerated approval based on liver histology, while also trying to show long-term cardiovascular benefits.
Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Hepatic (Liver)
- Immune Disorders
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- Genfit SA
- Senior Management
Jean-Francois Mouney, Chmn. & CEO
Nathalie Huitorel, EVP, CFO & Chief Administrative Officer
Dean Hum, PhD, COO
Carol L Addy, MD, CMO
- Contact Info
Phone: (33) 3 20 16 40 00
885 Ave. Eugene Avinee
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.